糖基化纤连蛋白可提高早孕期子痫前期的预测效能
本研究为亚洲中国单胎妊娠女性的巢状病例对照研究,于孕11–13周筛查子痫前期, retrospectively检测存档血清糖基化纤连蛋白(GlyFn),比较ELISA与床旁检测(POC)一致性,并评估GlyFn加入FMF三联试验后对早产型及任何类型子痫前期的筛查效能。结果显示加入GlyFn后早产型子痫前期AUC由0.859升至0.896,10%假阳性率下检出率由64.9%升至82.9%。
要点
- ELISA与POC检测GlyFn的一致性相关系数为0.86(95%CI 0.83–0.88),POC测值显著高于ELISA(斜率1.08,95%CI 1.04–1.14)。
- 早产型子痫前期孕妇ELISA GlyFn中位MoM为1.23 vs 非PE 1.00(P<0.0001);POC为1.18 vs 1.00(P<0.0001)。
- GlyFn加入FMF三联试验后早产型PE的AUC由0.859升至0.896(P=0.012),10%FPR下检出率由64.9%升至82.9%。
核心结论
- 在亚洲人群中,将GlyFn加入FMF三联试验可提高早产型及任何类型子痫前期的筛查敏感度;作者指出需前瞻性非干预研究证实这些初步发现。
研究设计与样本
- 巢状病例对照研究,纳入2016年12月至2018年6月于孕11–13周筛查子痫前期的中国单胎妊娠女性,ELISA检测1685例(含101例PE)存档血清,POC检测448例(含101例PE);以FMF竞争风险模型评估风险,参考标准为子痫前期发生及分娩孕周。
诊断标准与关键数值
- ELISA与POC一致性相关系数0.86(95%CI 0.83–0.88),Passing-Bablok斜率1.08(95%CI 1.04–1.14)提示比例偏倚且POC测值显著高于ELISA;早产型PE的ELISA GlyFn中位MoM为1.23 vs 非PE 1.00(P<0.0001),POC为1.18 vs 1.00(P<0.0001);足月型PE的ELISA为1.26 vs 1.00(P<0.0001),POC为1.22 vs 1.00(P<0.0001)。
临床应用与阅片要点
- 作者结论为在FMF三联试验基础上加入GlyFn可提高早产型及任何类型子痫前期的筛查敏感度,并指出需前瞻性非干预研究证实这些初步发现。
局限性
- 作者指出需前瞻性非干预研究证实这些初步发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether maternal serum glycosylated fibronectin (GlyFn) level in the first trimester increases the sensitivity of the Fetal Medicine Foundation (FMF) triple test, which incorporates mean arterial pressure, uterine artery pulsatility index and placental growth factor, when screening for pre-eclampsia (PE) in an Asian population.
METHODS: This was a nested case-control study of Chinese women with a singleton pregnancy who were screened for PE at 11-13 weeks' gestation as part of a non-intervention study between December 2016 and June 2018. GlyFn levels were measured retrospectively in archived serum from 1685 pregnancies, including 101 with PE, using an enzyme-linked immunosorbent assay (ELISA), and from 448 pregnancies, including 101 with PE, using a point-of-care (POC) device. Concordance between ELISA and POC tests was assessed using Lin's correlation coefficient and Passing-Bablok and Bland-Altman analyses. GlyFn was transformed into multiples of the median (MoM) to adjust for maternal and pregnancy characteristics. GlyFn MoM was compared between PE and non-PE pregnancies, and the association between GlyFn MoM and gestational age at delivery with PE was assessed. Risk for developing PE was estimated using the FMF competing-risks model. Screening performance for preterm and any-onset PE using different biomarker combinations was quantified by area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at a 10% fixed false-positive rate (FPR). Differences in AUC between biomarker combinations were compared using the DeLong test.
RESULTS: The concordance correlation coefficient between ELISA and POC measurements was 0.86 (95% CI, 0.83-0.88). Passing-Bablok analysis indicated proportional bias (slope, 1.08 (95% CI, 1.04-1.14)), with POC GlyFn being significantly higher compared with ELISA GlyFn. ELISA GlyFn in non-PE pregnancies was independent of gestational age at screening (P = 0.11), but significantly dependent on maternal age (P < 0.003), weight (P < 0.0002), height (P = 0.001), parity (P < 0.02) and smoking status (P = 0.002). Compared with non-PE pregnancies, median GlyFn MoM using ELISA and POC testing was elevated significantly in those with preterm PE (1.23 vs 1.00; P < 0.0001 and 1.18 vs 1.00; P < 0.0001, respectively) and those with term PE (1.26 vs 1.00; P < 0.0001 and 1.22 vs 1.00; P < 0.0001, respectively). GlyFn MoM was not correlated with gestational age at delivery with PE (P = 0.989). Adding GlyFn to the FMF triple test for preterm PE increased significantly the AUC from 0.859 to 0.896 (P = 0.012) and increased the DR at 10% FPR from 64.9% (95% CI, 48.7-81.1%) to 82.9% (95% CI, 66.4-93.4%). The corresponding DRs at 10% FPR for any-onset PE were 52.5% (95% CI, 42.3-62.5%) and 65.4% (95% CI, 55.2-74.5%), respectively.
CONCLUSIONS: Adding GlyFn to the FMF triple test increased the screening sensitivity for both preterm and any-onset PE in an Asian population. Prospective non-intervention studies are needed to confirm these initial findings. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Moungmaithong S, Wang X, Lau CSL, et al. Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2023. PMID: 37616523. doi:10.1002/uog.27451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。